StocksTelegraph
S&P 500NASDAQDOWRUSSELL
NASDAQ · IMNM·Healthcare

Immunome, Inc. (IMNM) Sentiment Analysis

Market Closed
$23.97
Prev Close
Market Cap
Day Range
52W Range
P/E
EPS (TTM)
Volume
Avg —
Beta
50
ST Score
50.1/100C+

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of
Sentiment factor
ST sentiment gradeHow the market currently feels about this stock versus its peers
Overall ST grade
C+
ST Score
50.1
Price change today
Analyst tilt
Strong buy
Buy
Hold
Sell
Strong sell
Bullish share0 bullish vs 0 bearish ratings
Recent headline tone

Headline tone is a simple keyword scan of recent coverage, not a prediction.

IMNM stock: frequently asked questions

What is IMNM's ST Score?

Immunome, Inc. (IMNM) has an ST Score of 50.1 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is IMNM a buy, sell, or hold?

Wall Street's consensus rating on IMNM is Buy based on 13 analyst ratings. Our own ST Score grades it C+ (50.1/100). This is data, not investment advice — always do your own research.

What is IMNM's valuation grade?

Immunome, Inc. (IMNM) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is IMNM's growth grade?

Immunome, Inc. (IMNM) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is IMNM's profitability grade?

Immunome, Inc. (IMNM) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is IMNM's financial strength grade?

Immunome, Inc. (IMNM) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is the analyst price target for IMNM?

The average analyst price target for Immunome, Inc. (IMNM) is $35.25 from 13 analysts, which is +0.5% versus the recent price of $23.97.

What is IMNM's Piotroski score?

Immunome, Inc. (IMNM) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.